Q2-osavuosiraportti
63 päivää sitten‧35 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
266 937
Myynti
Määrä
150 018
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 373 | - | - | ||
| 509 | - | - | ||
| 275 | - | - | ||
| 6 477 | - | - | ||
| 12 391 | - | - |
Ylin
2,445VWAP
Alin
2,38VaihtoMäärä
2,5 1 028 273
VWAP
Ylin
2,445Alin
2,38VaihtoMäärä
2,5 1 028 273
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 21.8. | |
| 2024 Yhtiökokous | 15.5. | |
| 2025 Q1-osavuosiraportti | 13.5. | |
| 2024 Q4-osavuosiraportti | 21.2. | |
| Merkintäoikeusanti | 3.12.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
16.10.·Do we have any good news here soon? :D
17.10.·When will they arrive? When is soon!!- 2.10.·Strengthened clinical leadership An experienced CMO with a good track record in oncology adds credibility to the company's clinical program (can give investors confidence that it is being developed competently). Regulatory expertise Dempke's experience with approval processes (NDA, clinical registration programs) can contribute to better interaction with regulatory authorities and more efficient study design. Strategic signal The company's prioritization of recruiting a strong clinical leader can be a signal that it is planning intensified clinical development, new studies or strengthened regulatory activities - all potential catalysts for the stock. Industry relations & networks A person with previous experience in large pharmaceutical companies may have contacts that facilitate collaborations, partnerships or investments.
4.10.4.10.We are delighted to present our study & partnership with @cantargia 🇸🇪 at #AACRPan25 to move fwd #IL1RAP inhibition as a strategy to improve chemoimmunotherapy sensitivity in #PancreaticCancer - some BIG news to come soon! @SylvesterCancer @PeterHoseinMD https://cantargia.com/en/press-r - 1.10.·Positive!
26.9.26.9.For those suffering from sudden movements: When investing in biotechs, you have to understand how the market works for them. 1. Successful phase 1/2 results usually provide quick and steep rises in stock price. So do rumors about partnerships. 2. Medical R&D is very expensive. These companies need money and thus dilute. In Cantargia's case, this happened many times and then crashed the price. Now they have money. 3. Biotechs rise often due to pump (and sometimes dump) in social media or mainstream sites & youtube (MarketBeat, Seeking Alpha..). But the rise is usually a temporary pump. Cantargia is not on their radar due to being a Nordic company. 4. It requires patience beyond any other sector. You just have to wait and believe there will be successful results from phase 3 and then a partnership or aquisition. The drug is very promising and the need for a working drug for pancreatic cancer is huge. The movement in price is completely normal until there will be successful result, and then partnership, or failure in comparison to placebo or failure to find a partner.
18.9. · Muokattu·I can't read this paragraph enough times: "When the transaction was completed in the first half of September, Cantargia received an initial cash payment of USD 33 million and is entitled to up to an additional USD 580 million in development, regulatory and commercial milestones. In addition, there are double-digit royalty-like payments based on future global sales" Senseless potential, so to speak. and that's just part of the cake!! Feels like it's slowly starting to sink in with people... and it will only get harder to manipulatively abuse the stock trading going forward!!25.9.·A familiar pattern for many weeks. The stock rises at the beginning of the day and creates hope, then falls at the end of the day and often ends up in the red, creating disappointment. The private shareholders give up and sell. Suddenly one day the big investors start buying and create a dramatic increase in the share price, and the small investor who sold is left on the platform.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
63 päivää sitten‧35 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 16.10.·Do we have any good news here soon? :D17.10.·When will they arrive? When is soon!!
- 2.10.·Strengthened clinical leadership An experienced CMO with a good track record in oncology adds credibility to the company's clinical program (can give investors confidence that it is being developed competently). Regulatory expertise Dempke's experience with approval processes (NDA, clinical registration programs) can contribute to better interaction with regulatory authorities and more efficient study design. Strategic signal The company's prioritization of recruiting a strong clinical leader can be a signal that it is planning intensified clinical development, new studies or strengthened regulatory activities - all potential catalysts for the stock. Industry relations & networks A person with previous experience in large pharmaceutical companies may have contacts that facilitate collaborations, partnerships or investments.4.10.4.10.We are delighted to present our study & partnership with @cantargia 🇸🇪 at #AACRPan25 to move fwd #IL1RAP inhibition as a strategy to improve chemoimmunotherapy sensitivity in #PancreaticCancer - some BIG news to come soon! @SylvesterCancer @PeterHoseinMD https://cantargia.com/en/press-r
- 1.10.·Positive!
- 26.9.26.9.For those suffering from sudden movements: When investing in biotechs, you have to understand how the market works for them. 1. Successful phase 1/2 results usually provide quick and steep rises in stock price. So do rumors about partnerships. 2. Medical R&D is very expensive. These companies need money and thus dilute. In Cantargia's case, this happened many times and then crashed the price. Now they have money. 3. Biotechs rise often due to pump (and sometimes dump) in social media or mainstream sites & youtube (MarketBeat, Seeking Alpha..). But the rise is usually a temporary pump. Cantargia is not on their radar due to being a Nordic company. 4. It requires patience beyond any other sector. You just have to wait and believe there will be successful results from phase 3 and then a partnership or aquisition. The drug is very promising and the need for a working drug for pancreatic cancer is huge. The movement in price is completely normal until there will be successful result, and then partnership, or failure in comparison to placebo or failure to find a partner.
- 18.9. · Muokattu·I can't read this paragraph enough times: "When the transaction was completed in the first half of September, Cantargia received an initial cash payment of USD 33 million and is entitled to up to an additional USD 580 million in development, regulatory and commercial milestones. In addition, there are double-digit royalty-like payments based on future global sales" Senseless potential, so to speak. and that's just part of the cake!! Feels like it's slowly starting to sink in with people... and it will only get harder to manipulatively abuse the stock trading going forward!!25.9.·A familiar pattern for many weeks. The stock rises at the beginning of the day and creates hope, then falls at the end of the day and often ends up in the red, creating disappointment. The private shareholders give up and sell. Suddenly one day the big investors start buying and create a dramatic increase in the share price, and the small investor who sold is left on the platform.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
266 937
Myynti
Määrä
150 018
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 373 | - | - | ||
| 509 | - | - | ||
| 275 | - | - | ||
| 6 477 | - | - | ||
| 12 391 | - | - |
Ylin
2,445VWAP
Alin
2,38VaihtoMäärä
2,5 1 028 273
VWAP
Ylin
2,445Alin
2,38VaihtoMäärä
2,5 1 028 273
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 21.8. | |
| 2024 Yhtiökokous | 15.5. | |
| 2025 Q1-osavuosiraportti | 13.5. | |
| 2024 Q4-osavuosiraportti | 21.2. | |
| Merkintäoikeusanti | 3.12.2024 |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
63 päivää sitten‧35 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 21.8. | |
| 2024 Yhtiökokous | 15.5. | |
| 2025 Q1-osavuosiraportti | 13.5. | |
| 2024 Q4-osavuosiraportti | 21.2. | |
| Merkintäoikeusanti | 3.12.2024 |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 16.10.·Do we have any good news here soon? :D17.10.·When will they arrive? When is soon!!
- 2.10.·Strengthened clinical leadership An experienced CMO with a good track record in oncology adds credibility to the company's clinical program (can give investors confidence that it is being developed competently). Regulatory expertise Dempke's experience with approval processes (NDA, clinical registration programs) can contribute to better interaction with regulatory authorities and more efficient study design. Strategic signal The company's prioritization of recruiting a strong clinical leader can be a signal that it is planning intensified clinical development, new studies or strengthened regulatory activities - all potential catalysts for the stock. Industry relations & networks A person with previous experience in large pharmaceutical companies may have contacts that facilitate collaborations, partnerships or investments.4.10.4.10.We are delighted to present our study & partnership with @cantargia 🇸🇪 at #AACRPan25 to move fwd #IL1RAP inhibition as a strategy to improve chemoimmunotherapy sensitivity in #PancreaticCancer - some BIG news to come soon! @SylvesterCancer @PeterHoseinMD https://cantargia.com/en/press-r
- 1.10.·Positive!
- 26.9.26.9.For those suffering from sudden movements: When investing in biotechs, you have to understand how the market works for them. 1. Successful phase 1/2 results usually provide quick and steep rises in stock price. So do rumors about partnerships. 2. Medical R&D is very expensive. These companies need money and thus dilute. In Cantargia's case, this happened many times and then crashed the price. Now they have money. 3. Biotechs rise often due to pump (and sometimes dump) in social media or mainstream sites & youtube (MarketBeat, Seeking Alpha..). But the rise is usually a temporary pump. Cantargia is not on their radar due to being a Nordic company. 4. It requires patience beyond any other sector. You just have to wait and believe there will be successful results from phase 3 and then a partnership or aquisition. The drug is very promising and the need for a working drug for pancreatic cancer is huge. The movement in price is completely normal until there will be successful result, and then partnership, or failure in comparison to placebo or failure to find a partner.
- 18.9. · Muokattu·I can't read this paragraph enough times: "When the transaction was completed in the first half of September, Cantargia received an initial cash payment of USD 33 million and is entitled to up to an additional USD 580 million in development, regulatory and commercial milestones. In addition, there are double-digit royalty-like payments based on future global sales" Senseless potential, so to speak. and that's just part of the cake!! Feels like it's slowly starting to sink in with people... and it will only get harder to manipulatively abuse the stock trading going forward!!25.9.·A familiar pattern for many weeks. The stock rises at the beginning of the day and creates hope, then falls at the end of the day and often ends up in the red, creating disappointment. The private shareholders give up and sell. Suddenly one day the big investors start buying and create a dramatic increase in the share price, and the small investor who sold is left on the platform.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
266 937
Myynti
Määrä
150 018
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 373 | - | - | ||
| 509 | - | - | ||
| 275 | - | - | ||
| 6 477 | - | - | ||
| 12 391 | - | - |
Ylin
2,445VWAP
Alin
2,38VaihtoMäärä
2,5 1 028 273
VWAP
Ylin
2,445Alin
2,38VaihtoMäärä
2,5 1 028 273
Välittäjätilasto
Dataa ei löytynyt